CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...

GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs ...

--On pace for largest percent increase since Dec. 6, 2022, when it rose 7.85% --Down 51.37% from its all-time closing high of $76.92 on Jan. 6, 1999 ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...

GlaxoSmithKline plc (NYSE: NYSE:GSK) shares gained 5.65% after the pharmaceutical giant reported fourth quarter revenue that beat analyst estimates, despite earnings falling short of expectations.

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price ...

(Reuters) - European shares were flat in early trade on Wednesday, as gains led by healthcare stocks following drugmaker Novo ...

Pharmaceutical giant GlaxoSmithKline (GSK) has lifted its long-term sales guidance as it hailed a strong drug pipeline. It came as the boss of the London-listed firm cheered an “excellent” performance ...

The 30th Nigerian Economic Summit (#NES30) was held in Abuja on October 14, 2024. At that summit, the Vice President of the ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 21.25%, which has investors questioning if this is right time ...

In fact, it’s starting already. Ahead of JP Morgan’s biotech jamboree this month in San Francisco, Johnson & Johnson (J&J), ...

Explore the detailed Glaxo Smith Kline balance sheet to understand the company’s financial health and stability. This page provides a clear breakdown of key metrics, including total assets ...